Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma GmbH
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINATION WITH MMF (CELLCEPT®) AND STEROIDS IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION
The study aims to evaluate and to compare the efficacy and safety of a triple modified release tacrolimus FK506E (MR4) / MMF / steroid regimen with a triple standard tacrolimus FK506 / MMF / steroid r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN
To assess the safety of a tacrolimus modified release, MR4, based immunosuppressive regimen in stable kidney transplant subjects converted on a 1:1 (mg : mg) basis from a Prograf based immunosuppress...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSPLANTATION
Primary objective of this study is to compare the two therapy regimens (Arm 1: tacrolimus + sirolimus + corticosteroids, Arm 2: tacrolimus + MMF + corticosteroids)with regard to renal function by usin...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINATION WITH STEROIDS IN PATIENTS UNDERGOING PRIMARY LIVER TRANSPLANTATION
To evaluate and to compare efficacy and safety of a dual regimen with oral modified release tacrolimus FK506E (MR4) / steroids versus a dual regimen with oral tacrolimus FK506 / steroids in patients u...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR MYCOPHENOLATE MOFETIL IN LIVER ALLOGRAFT TRANSPLANTATION
The objective of this study is to evaluate the efficacy and safety of two regimens (Arm 1 and Arm 2) containing tacrolimus and minimal steroids together with either monoclonal anti-IL2R antibodies (da...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN
To assess the safety of a tacrolimus modified release, MR4 , based immunosuppressive regimen in stable liver transplant subjects converted on a 1:1 (mg:mg) basis from a Prograf® based immunosuppressi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant patients
The objective of this study is to obtain information on the pharmacokinetics of tacrolimus when used in combination with everolimus in stable kidney transplant patients.
Country
None
organs
None
Specialty
None
Closed trial
More information